aa 8-1會期部長業務報告-書面報告.pdf
TRANSCRIPT
-
1
8 1
()
1. 100 7 1 101 2 19 1,118 1,644 B
2. 100 266 7,665 100 10 1 65 6 100 2 13 257.4 97.5%
-
2
3. 25% 100 12 1 101 3 31
4. 1 101 1 3
2 16 24
288 86
3
4 101 2 17 2,856
5
6 9 1 2 ICU
-
3
3 /4
() 1. 71
100 58 3 101 2 19 11
2. 100 71
3. 71
4. 100
5.
-
4
5 100
()
1. 1001012191,5431,165 149 99 95 24 4411 1 10 13 (101)(100)
2.
3. 100 9
1 100 9 13 100 11 21 10 20
-
5
100 6 1 10 21 28 10 11
210 100 20
4. 101 1
2
3
-
6
4
5
6
()
1.
2. (DOTS)100 14,607 90%
3. (MDR) 96 5 100 100 212
4. 100 4,842 99 98
()
1. 3
-
7
0800-010-569
2. 100 12 21 () 928 374 1 100 1 12 28 8,751 349 90%
3. 100 1 12 7 5,040
4. 96 100 45 100 12 10,240
()
1. 100 100
-
8
490 100 10 100%
2. 99 2011 Asia Pacific Hand Hygiene Excellence Award 323 100 7 311
3.
4. carbapenem
5. 100 100 33 44
-
9
()
1. (OPV) 100 9 Tdap-IPV
2. 5 99 (PCV)101 PCV 5 4.3
3. 100 10 75
4. /
()
1. 100 9 16
-
10
1
2
3 63
50 4
2. 98
100 12 191 19 79 24 55 112 191
3.
1 9 17 24
-
11
2 13 8
() 1.
99 7 1 100 82 204 520
2. 100 39 601
3. 14 100 12 136 2 1,000
4.
-
12
100 12 48 103 1 1
5. 100 19
6. 100 100 5 45 7 40
() 1. 9
19,143 4
2. 110 105 96 1 4,131 100 3 6,628 94 71.5% 100 5%
-
13
3. /100 6.51 16.54
()
1. 100 22 300 100 12 123,748 480,195 3.88 43.37%
2. 97 7 4 99 1,696 95%100 12 1,211 1,164 96.12%99 27 100%100 12 40 39 97.5%
3. 99 3,889 10
-
14
16.8 98 4,063 10 17.6 174 4.3% 86 10 11 100 1-11 3,102 99 494 14%
() 1.
505 238 7 14
2. 100 136 4 73 5
3. /58
4. 1 10
-
15
(2) 3 1
2
3
() 1. 6
11 2. 100 1 1
200
3. 100
4.
5. 1100
-
16
83 37
2100 11 1
3 100 100 8
4100 15
6. 1 100 225 5 295 100
2,918 ( 1,450 1,468 ) 3100 69
2,488 101 80 4 100
101
7.
-
17
1003248()1553.4
8. 10092839
() 1.
2.
3.
-
18
4.
5. 6
() 1. 1
100 12 276
2 100 12 208
3 100 12 150
2. 100 12 IC 32
3. 100 12 198 175
-
19
() 1.
2. 100 85 3 0,524 3,655 7,248 1 8,813 948 5 6,700 4,480
3.
1100 619 3
2() 115 135 6 62 1
3 64 79 1 8
4. 24
-
20
100 301 275 91.4%
5. 100 776100 32 27
6. HIS 100 48 32 (PACS)100 3,364
() 1. 1
2(22 )(63 )(368
) 3()
4
-
21
2. 1
99 100 12 99 99 100 12 4,330 99 100 1 5,117
2() 99 5100 8
3. 1 1
97 2.3%98 5.7%99 16.3% 100 21%
2 100 61,675 97 3.5
-
22
3 6,346 45 CDR
2 100 99 100 30
4. 7 7 8
5. 98 7 23
1 99 35 2.98%100 ( 1 )
-
23
100 11
2 100 4 101 7,000
3 100 7 1,900 1017
4()()
5
6 98 9 100 11
-
24
81 225
()
1. 99 4 1 100 12 62
2. 100 1 26
3. () 100 12 17.69
-
25
4. 100 12 680 2.72%
5. 7 100 12 1
()
1. 1(Tw-DRGs)
299 1 155 100 1 164 17% 1,029 60% 5 100 1 18
-
26
DRG
3(Tw-DRGs)
4 100 1 11 4.39 4.17 5.01% 4 5,474 4 5,314 160 0.35%
2. 1100
2 100 2 23 3
-
27
25 7 15 100 7 1 103 6 30 101 1 1 103 12 31 3
3
3. 100 14.78 100 1 1 17% 2 3 4 101 21.4 100 9 16 17 101 9.099 12.389 100 8 RBRVS 37 100 9 11
-
28
101 3
4. (1)(2)(3) 3 100 377.2
()
1. 100 12 307 226
2. 1100 12
3,872 2.41 18.7 43.79 2,646 1,806
2100 100 12 1.48 3.5
-
29
3. 100 12 5,128 1 4,078
4.
100 12
118 17.8
2 16.9 3
5.1
5. (IDS) 48
()
1. 90
-
30
99 12 20 5
2. 99 150() 100 ()
3.
4. 98 12 100 190 55 0.099 5%
() 1. 100 1
4 100 1 26 1 2
2.
-
31
1
2
3 30 16
4
5
6
-
32
101 2 19 1668 ( 108 )
()
1. 100 481 46 2,110 200 100 12 145
2. 100 55 481
() 1. 1100 259
2100
3,141 2,955 94.1%
3 100 1 1
-
33
100 42 0,774
4 100 3 20() 100 12 31 17,188 3 12 3 26 ()
5 101 18
2.
1100 5 28
-
34
5 100 5 31 614 8 1
2 100 5 31 7 20 4 9,652 4,076 2 9,337 6 11 100 7 28 5723.2617 18.7948 5704.4669 100 7 29
3 5 28 7 25 131 4,150 100 1,099
-
35
4 100 7 20 49 3,180 20
5 31 34 100 6 22
6 100 7 13 (TDI) 100 10
-
36
7
393 4,266
3. 1
99 9 9 0991301731 100 1 1 101 4 30 100 12 606 99 11 29 0991302917 101 4 30
2 100 9 28
()
-
37
1. cGMP 100 12 162 10 3 22 145 GMP 34 PIC/S GMP
2. 100 1,041 203 20 201 1 2 600 8 5 1
3. 99 1 100 12 1 6,562 4 7,358.3 99 1 13.9% 100 12 4.95%
4. (1)
(2)
-
38
(3) 100 140 30 27
(4) 100 826 163 663 51
(5) 100 284
5. GMP 116 100 GMP 60
6. 100 262 13
7. 100 385 2,346.9
8. 100 7 20
9. 100 8 29 100 12 1 100 67
10. 18
11.100 10 15 16 100
-
39
31 51 7
12.Journal of Traditional and Complementary MedicineJTCM 100 10 10
13.100 2
() 1. (1)
100 121 99 67
(2)
(3) (DMF)100 6 21 (DMF)
(4) 100
-
40
12 (General Clinical Research Center,GCRC)
(5) 100 11 1 101 1
2. (1)
(2)
() 1.
100 15,247 143 0.94%
2. 100 16,351 99 1 8,792 13.0%
3. 100 6 2 4 6 14
-
41
4. 1 2 98 11 10
()
1. 100 12 431 100 3 3 96 100 12 6 1
() 1. 10 1 99
153 1 98.3%100 1 10 153 94.05% 99 100 100 10 1,015 101
-
42
2. 100 1 11 1
1,656 300 19 1,613 3,206 4,059 1,639 100 1 12 19 7,789 3,206
3. 100 1 12 1 461 608 5,821
4. 100 12 158 71.4%99 67.2% 1 99 58.5% 100 61.8%99 11 24 100 5 11 100 12 1,548 99.8%
5.
-
43
28 4 1 10 50 99 1.090 100 1.079 16 1.134 18
6. 99 12 8 100 4 7
-
44
100 1 1 100 12 29 3 4
()
1. 4 5100 1 12 35 2,375 97.4% 98%
2. 99 100 1 10 42 101 100 1 12 3 4 17 9,898 91.38% 97%
3. 5 1 99 27 7,639 100 1 10 25 4,971 100 22 2,661152
4. 7 7 99 1031 1 98.3%100 1 10 84 80.5% 100
-
45
5. 22 1 6 14 2 4 42
6. 99 100 26 22 4 8 99 100 2 4,400 99 100 2 3
7. 99 3 12 5,054 100 1 10 2,039
-
46
8. e 100 1 12 39 735 3,045 31 Teens 9 1,981 19 87 113 2 6,264 62 51 414 msn 217
()
1. 40 64 3 1 55 65 1 99 178 100 1 11 170
2. 3 103 6 166 14 416 582
3. 18 62.3%
-
47
44.6% 4. 20
22 7 5 3,843 2 3,958 3 6,418 90%
5. 687 1,986 2 5
6. 45 16 18 9 2
7.
8. 100 536 1,400
9. 483
-
48
100 174 101 101 186 22 100 6,532 4,239
10. 2011 Diabetes Education and Prevention 4,000
11. 100 126 2 1,401 6 3,357 50 33 22 2,881 12 5,305 65
12. 100 9 65 81 100 1 12 50 69 42.6 50-69 76.4 65
-
49
537 100 1 10 3,959
13. 100 1222 1,333 477 26%99 100 60%
14. 99 100 100 12 13 101 1 19 7 20 105 186 11 15 10 3 3
15.
-
50
WHO-99 100 9 20 101 20
16. 100 12 22 929 3 424
()
1. 18 99 64.1% 100 65.1%
2. 91 22
-
51
1 8,970
3. 8 45 100 12 30 101
4. 100 16 104 107 4
5. 100 13
6. AFHC 100 12 7 11 AFHC2
-
52
30 2 34 9 3,000
7. 100 1 12 2 417
8. 94 100 29 100 12 19
9. 96 100 100 12 46
10. 100 3 1
11. 1 100 12 76 WHO
-
53
100 6 19 101 20
2 100 12 4 Health Care Without HarmHCWHThe First Global Climate and Health Summit WHO TF on HPH and Environment 12 6 HCWH UNFCCC 17 WHO Dr.Maria NeiraHCWH Josha Karliner 50
3 100 12 8 UNFCCC 17 Climate Change and Public Health: Healthy Climate, Healthy People, Healthy Economy WHO TF on HPH and Environment WHO The First Global Climate and Health Summit
-
54
12. 96
100 12 7,411 303
13. 3,696
14. 100 100 1 460 92 604 ( 39.84%) 126
() 1. 22 100
60 600 22
-
55
2.
3.
4.
5. 100 12 31 1 1,880 72 1,104
() 1. 100
99 19.8% 19.1%99 9.1% 8.2%
2. 100 1 12 38 1,864 1 130 8,770 796 647
3. 100
-
56
4. 100 101 53 32
5. 100 85 448 44
6. 100 183 3 5412
7. 100 1 12 8,567 50
-
57
8. 100 1 12 9 8,486 1,957 100110108,922
9. 49 100 12 953 9 8,267 9,706 3 6,746 3 87.64%( 5,912)
10. 98 6 4 100 12 112 2,223
()
1. 97 174.4 99 171.3 1.8% 97 10 94.4 99 93.9 0.5% 104 98 10%
2. 92 96 41.1% 93 97 42.3% 1.2%
-
58
58.1% 59.2% 1.1% 3. 100
1 12 431 214 55.7 76.4 84.9 101 1 12 4,320 9,360 2,584 1,641 1 6,078 1,319 1,591
4. 100 36 6 HPV100 1 12 6.1
5. 100 HPV 3,654 3 HPV 48% 1,980 3 HPV 14%
6. 228 69
7. 100
-
59
100 8 1 97 39 8
8. 69 100 1 12 2 99 1 42% 98 39% 3%
()
1. 100 12 765 54 100%
2. 5 1 4
() 1. DBPR104 99
7 30 11 23 FDA
-
60
2. DBPR108
3. 8 50 33 100 9
4. H5N1 1 1 100 6 99 8 2
-
61
5. B 100
6 17 100 7 22 B
6. /
7. AURORA Imaging Technology, Inc.
8.
-
62
()
1. 64 2005 14 10
2. (WHO) 100 5 16 6 (Mr. Burci) 4 Burci (take note of)
3. 100 10
-
63
4. APEC (HWG)(2011-2012)(Health Policy Dialogue) 100 3 9 9
5. APECRFID APEC 100 7 5 6 170 32 APEC 13
6. 100 9 24 25 2011 210
() 1.
-
64
3 100 12 19 9 13 (LNSP)
2. 100 7 449
3. 6000
4. (TaiwanIHA)(AMDA) 8 1 9 130
()
1.
-
65
2.
3. 100 23 146
4. 100 6 26 8 1 2
-
66
()100 51 1,443 66 582 4
1. (1)
(2) (3) (4) 2. (1)
(2)
-
67
(3) (4) (5)
1. APEC
2. 3. (1) (2) (3) (4)
1. (1) (2) (3) 2. (1)101
-
68
(2) 3. (1) 2
(2) 20 (3) (4)
1. 2. 55 64 3.
4. 5.
6. HPV
7.
1. 2. CDC 3.
-
69
4. Gastein European Health Forum 5.
11 45
-
70
96 98 100
1.
2.
3. 4.
2143 1500-1700
-
71
1.
2. 3. 4. 5.
1.
2.
-
72
IDS
3. (101-105 )
4.
1.
2. 101
1. 99 4 1
2.
-
73
1.
6 ()
2. 36
DRG
1. DRG
2.
-
74
100 1 26
30
1. 3
2.
3.
-
75
10-15 4.
1. 2. 3.
1. 71
2. 71
-
76
PCV 102-104 PCV
-
77
MIT
-
78
1.
2. 290
3.
4. 101 6
5. 100 101 102 101
-
79
102
101
-
80
-
81